UnitedHealth Group (UNH) received several positive revisions from Wall Street analysts after a strong second-quarter earnings report. On Friday, UBS Group raised its price objective on the healthcare company to $490.00 from $460.00. UBS Group maintains a "buy" rating. The consensus 12-month price target from analysts rose to approximately $471.8, suggesting potential upside.
This optimism follows UnitedHealth's recent announcement of better-than-expected quarterly results. The company also raised its full-year 2026 adjusted earnings per share guidance to a range of $19.50 to $20.00. In recent days, other firms like Piper Sandler and Baird also increased their price targets, citing the company's strong performance and improved outlook.